Divalproex Sodium Extended-Release Tablets Recalled for Failed Dissolution Specifications
Amneal Pharmaceuticals is recalling 4,309 bottles of Divalproex Sodium Extended-Release Tablets (250 mg) due to failed dissolution specifications. The tablets may not dissolve properly, potentially affecting medication effectiveness.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II drug recall with no reported illnesses or injuries. However, failed dissolution specifications on an essential medication represent a risk of harm—the medication may not release properly, potentially causing therapeutic failure. This fits the rubric criterion for 'risk-of-harm products where injury has not yet been reported.'
Plain-English summary
Amneal Pharmaceuticals of New York, LLC issued a recall of Divalproex Sodium Extended-Release Tablets, USP, 250 mg. The recall affects 4,309 bottles from Lot #AR210705, which expires in April 2024. The product was distributed nationwide in the United States and can be identified by package NDC 65162-755-10 and related NDCs.
The recall was initiated due to failed dissolution specifications, meaning the tablets do not meet standards for how they dissolve and release the active medication in the body.
Patients and healthcare providers who may have this medication should check the lot number on the bottle to verify whether they possess the recalled product.
The recalled product
- Product
- DIVALPROEX SODIUM (DIVALPROEX SODIUM)
- Brand
- DIVALPROEX SODIUM
- Manufacturer
- Amneal Pharmaceuticals of New York, LLC
- Category
- Drug
- Affected units
- 4,309
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AR210705
- Exp 04/2024
UPCs (2)
- 0365162755107
- 0365162757101
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DIVALPROEX SODIUM
- ModerateDivalproex Sodium Delayed-Release Tablets Recalled Due to Presence of Foreign Tablets
FDA (Drugs) · 2026-07-29
- HighDivalproex Sodium 250 mg tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-04-03
- HighFDA Recalls Divalproex Sodium Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2022-08-03
- ModerateMajor Pharmaceuticals Recalls Divalproex Sodium Tablets Due to Humidity Exposure
FDA (Drugs) · 2019-08-07
- HighDr. Reddy's Recalls Divalproex Sodium Tablets for Dissolution Failure
FDA (Drugs) · 2019-02-27
Same manufacturer · Amneal Pharmaceuticals of New York, LLC
See all →- HighMethylergonovine Maleate tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-05-08
- SevereVancomycin Hydrochloride Oral Solution Recalled Nationwide for Superpotency Due to Overfilling
FDA (Drugs) · 2024-04-24
- ModerateFDA Recalls Oseltamivir Phosphate Oral Suspension for Out-of-Specification Impurities
FDA (Drugs) · 2024-02-28
- HighAmneal Phenoxybenzamine Hydrochloride Capsules 10mg Recalled Due to Unknown Impurity
FDA (Drugs) · 2024-02-14
- HighPrescription Drug Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2023-11-15
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22